Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
About This Trial
- This clinical trial is studying a targeted internal radiation treatment, guided by detailed MRI scans, for patients whose prostate cancer has returned after previous radiation therapy.
- It is designed for adults who have rising PSA levels and cancer that has come back only in the area where the prostate used to be.
- To be eligible, your cancer must not have spread to distant parts of your body, and you must not have had severe bowel or urinary complications from prior radiation.
- Before considering this study, patients should know that it involves a procedure to deliver radiation directly inside the body as well as multiple MRI scans.
More Information
- This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This clinical trial is studying a targeted internal radiation treatment, guided by detailed MRI scans, for patients whose prostate cancer has returned after previous radiation therapy.
Study Details
- Start Date: August 8, 2024
- Lead Sponsor: University Health Network, Toronto
Full Eligibility Criteria
Inclusion Criteria
- Patients who received previous RT to the prostate bed +/- pelvic nodal regions
- Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan
- At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl
- With or without ADT PSA doubling time from nadir greater than 6 months
- ECOG 0-2
- Age greater than 18 years
Exclusion Criteria
- Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases
- History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT
- Any contraindications to MR and/or brachytherapy
Treatments
- Radiation: High Dose Rate Brachytherapy

